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Abstract
Lichen sclerosus (LS) is a chronic inflammatory mucocutaneous disease with uncertain
etiology. It occurs as white plaque-like lesions mostly in the anogenital skin. Oral mucosal
involvement is extremely rare. This study aims to summarize the features of published oral
lichen sclerosus (OLS) and two new cases. A systematic search of the English literature
from 1955 to 2016 was performed in MEDLINE, Scopus, and Web of Science, and cross-
references were searched manually. Search phrases included “lichen sclerosus,” “mouth,”
“oral,” “lip,” “palate,” “floor of mouth,” “tongue,” “gingiva,” “buccal mucosa,” and “mouth
diseases.” Cases with clinical and histopathological confirmation of diagnosis of OLS were
included. A total of 41 (39 published and 2 new) histologically confirmed OLS cases were
available. The median age of OLS patients was 31 years, and 66% of the patients were
female. Most of the OLS lesions were asymptomatic. They were located in the labial
mucosa (n = 20), lip (n = 15), buccal mucosa (n = 14), gingiva (n = 12), tongue (n = 12),
and palate (n = 7). OLS is rare and typically presents as asymptomatic, white, plaque-like
lesions. Malignant transformation of preexisting OLS has not been reported.
Introduction
Lichen sclerosus (LS) is a relatively rare chronic inflammatory
mucocutaneous disease of uncertain etiology. The prevalence of
LS is estimated to be 0.1–0.3%.1 The disease is more common in
women and may be found in both children and adults with a typi-
cal onset before puberty in children, after menopause in women,
and in the fourth decade in men.2 LS was first described in 1887
by Hallopeau in his article “Du lichen plan et particulierement de
sa forme atrophique: lichen plan sclereux.”3 LS involving the oral
mucosa was first described by Miller in 1957.4 LS has been previ-
ously called lichen sclerosus et atrophicus and balanitis xerotica
obliterans, but the name was changed to lichen sclerosus in 1976
by the International Society for the Study of Vulvar Disease,
because atrophy is not always present in the lesions.5
LS presents clinically as ivory or porcelain-white, polygonal,
flat-topped papules, plaques, or atrophic patches.6 LS occurs
mainly in the anogenital area but may arise anywhere on the
skin with upper back, chest, and breasts affected most fre-
quently.6 About 60% of women with genital LS have symp-
toms.6 The symptoms of genital LS are itching, fissuring,
erosion, dysuria, urethral and vaginal discharge, dyspareunia,
and burning pain in females and hemorrhage, shallow erosions,
phimosis, paraphimosis, and urethral meatus stenosis in men.
Cutaneous LS is usually asymptomatic but can feature pain and
pruritus. Genital LS is associated with an increased risk of
malignant transformation.6 Differently, malignant change in
extragenital LS lesions is extremely rare.7
The etiological factors of LS are still uncertain, but infections
(e.g. Borrelia burgdorferi and Epstein–Barr virus infections),
autoimmune reactions, irritation (urine), hormones, and genetic
factors have been suggested to play a role in the pathogene-
sis.2 A growing consensus is that LS has an autoimmune etiol-
ogy in genetically susceptible individuals.2,8
The most characteristic histopathological feature of LS is
hyalinization of the lamina propria.8 Early LS lesions show
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subepidermal edema with a band-like lymphocytic infiltrate and
vacuolar alteration of keratinocytes.6,8 More advanced lesions
also show epidermal hyperkeratosis and atrophy with efface-
ment of the rete ridges, and loss of elastic fibers.2,6,8 Clefting
and blisters may result from subepidermal edema and interface
dermatitis.8
Oral LS is very rare. To the authors’ knowledge, there are
only 39 histologically proven reported cases of OLS in the Eng-
lish literature. However, LS affecting the lip may be underre-
ported.9 OLS is rarely symptomatic but can cause pain,
soreness, pruritus, and tightness when opening the mouth.10–17
Gingival lesions may cause gingival recession, loss of periodon-
tal attachment, and even tooth mobility.13,14,16 Malignant trans-
formation of OLS has not been reported.
The aim of this study was to summarize the demographic
and clinicopathologic data of LS involving the oral cavity and
lips for the first time in a systematic review. In addition, we
report two new cases of OLS.
Materials and methods
The review was done according to the PRISMA statement
guidelines. Three databases were searched for English case
reports and case series of OLS (Fig. 1). Search phrases
included “lichen sclerosus,” “mouth,” “oral,” “lip,” “palate,” “floor
of mouth,” “tongue,” “gingiva,” “buccal mucosa,” and “mouth
diseases.” The inclusion criteria were case reports or case
series with clinical and histopathological description diagnostic
of OLS. Exclusion criteria were LS of skin or anogenital mucosa
without oral lesions or no histological confirmation of clinical
diagnosis. After duplicates were removed, the publications were
reviewed by TK and MS.
Database: Scopus
Time range: 1.1.1960-12.11.2016
Search phrase: ( TITLE-ABS-KEY ( lichen  
sclerosus )  AND  TITLE-ABS-KEY ( lip  OR  
mouth  OR  oral ) )  OR  ( TITLE-ABS-KEY ( 
lichen  sclerosus )  AND  TITLE-ABS-KEY ( 
palate  OR  floor  of  mouth  OR  tongue  OR  
gingiva  OR  buccal  mucosa ) )  AND  ( LIMIT-
TO ( LANGUAGE ,  "English" ) )
Results: 259
Records after duplicates removed
(n = 293)
Abstracts screened
(n = 103)
Records excluded (n = 190) 
- titles did not match inclusion 
criteria
Full-text articles assessed 
for eligibility
(n = 35)
Full-text articles excluded (n = 5)
- no histopathological
confimation of diagnosis
Studies included in
qualitative synthesis
(n = 30)
Database: Medline(Ovid)
Time range: 1.1.1955-12.11.2016
Search phrases: 
1     Lichen Sclerosus et Atrophicus/and 
(exp Mouth Mucosa/or exp Mouth 
Diseases/)
2     limit 1 to english language
Results: 35
Database: Web of Science
Time range: 1.1.1960-12.11.2016
Search phrase: 
(TS = (Lichen sclerosus) AND TS = ((mouth 
or oral or lip or "palate" or "floor of mouth" 
or "tongue" or "gingiva" or "buccal 
mucosa"))) AND LANGUAGE: (English)
Results: 126
Abstracts exluded (n = 68)
- abstracts did not match
inclusion criteria
Fig. 1 Flowchart of database searching
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Clinical information of the present two cases were collected
from the patient records of Kuopio University Hospital, Finland
(Case 1), and from information included in a consultation case
from Kainuu Central Hospital, Finland (Case 2).
Histopathological slides of the cases were retrieved and re-
examined. The data were analyzed with descriptive statistical
methods.
The study plan was approved by the Regional Ethics
Committee of the Northern Ostrobothnia Hospital District. The
systematic review was registered to the PROSPERO register
(registration number CRD42017064920).
Case reports
Case 1
A 28-year-old female was referred to the Department of Oral
and Maxillofacial Diseases at Kuopio University Hospital owing
to oral mucosal changes. The patient had multiple sclerosis
(MS), allergies to pollen and sulfonamide, and was a smoker.
The patient had a history of pain, edema, and vesiculation in
the right side of the hard palate. A biopsy had been taken
14 months previously from the symptomatic area. The
histopathological diagnoses were nonspecific chronic inflamma-
tion and chronic lichenoid inflammation with a suspicion of
pemphigoid.
Clinical examination revealed diffuse, plaque-like, white
lesions on the right buccal mucosa near the corner of the
mouth, on the right side of the palate, and on the buccal gingiva
of the upper right canine (Fig. 2a–c). The lesions were not pru-
ritic nor painful. The patient did not have lesions in the genital
area or skin.
The palatal lesion was biopsied, and histological examination
showed atrophic stratified squamous epithelium with a thin
parakeratinized layer and occasionally visible stratum
(a) (b)
(d) (e)
(f) (g)
(c)
Fig. 2 Clinical and histopathological features of OLS.
Case 1: Whitish plaque-like lesions in the buccal mucosa (a), palate (b) and gingiva (c). Atrophic (Atr) epithelium and hyalinized connective
tissue (Hyal) with underlying lymphocytic inflammatory infiltrate (Infl) (d, e)
Case 2: Hyperkeratotic epithelium (Hke), slight hydropic degeneration of the basal cells, subepithelial homogenization, and lymphocytic
inflammatory infiltrate in the connective tissue (f, g). H&E, original magnification 9100 (d, f), 9200 (e, g)
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granulosum. Hydropic degeneration of the basal cells and slight
clefting in the epithelium-connective tissue junction were seen
in areas. There was scantiness of cells and hyalinization in the
lamina propria. A dense inflammatory infiltrate was present in
deeper connective tissue. The histological features were consis-
tent with LS. Differential diagnosis included morphea.
Immunofluorescence (IF) examination of fresh tissue from the
palate was also performed, and it showed linear IgG, IgM, and
fibrin deposits along the basal membrane. Indirect IF did not
reveal circulating anti-skin (intraepidermal or basement mem-
brane) antibodies. No treatment was administered because of
the patient being pregnant.
After 13 months, at follow-up examination the previous oral
lesions were unchanged, and a new small, white, plaque-like
lesion was noticed on the left side of the tongue (not shown).
All the lesions were asymptomatic. A new biopsy was per-
formed from the gingival lesion in the upper right canine region.
Histopathological examination showed a thin parakeratinized
layer over thinned stratified squamous epithelium, basal
destructive changes, clefting along the basal membrane, hyalin-
ization of connective tissue, and chronic inflammatory cell infil-
trate in deeper areas of the connective tissue (Fig. 2d, e). IF
examination of the second biopsy was negative for antibody
deposits. The histopathological diagnosis was LS.
Case 2
A 51-year-old generally healthy, nonsmoking woman with two
oral lesions was seen at Kainuu Central Hospital in Kajaani.
One of the lesions was bullous and located on the palatal
mucosa, whereas the other lesion, resembling leukoplakia, was
found on maxillary alveolar mucosa. The clinical features were
suspicious for mucous membrane pemphigoid.
The palatal lesion was excised. Histological examination
showed subepithelial blister formation and homogenization,
hyalinization of collagen fibers, hydropic degeneration of the
basal cells, band-like lymphocytic inflammatory infiltrate in the
connective tissue, telangiectasia, and lack of elastic fibers
(Fig. 2f, g). The amount of melanocytes was within normal
range. The patient was given the diagnosis of LS. Later, LS
lesions were also found in the vulva and perineum. At a follow-
up examination after 18 months, no new lesions were found.
Results
Literature review yielded a total of 39 histologically proven
cases of OLS (Fig. 1). Most papers reported only one case
(n = 25), one reported six cases,17 and four reported two
cases.18–21 The present report adds two new cases of histologi-
cally confirmed OLS, raising the total number so far to 41.
Summary of the demographic and clinical characteristics of
the OLS cases is presented in Table 1. More detailed data
about the patient characteristics are shown in Table S1. OLS
was reported from four continents (Asia, Europe, North
America, and South America). Mean age among the patients was
34 years (range 7–70). Sixty-six percent of the patients were
female. Five of the patients, including present case 1, were
smokers, 21 were nonsmokers, and for the rest, the reports did
not specify whether or not the patients smoked cigarettes.
Twenty-one (70%) patients were generally healthy. Nine (30%)
patients were reported to have medical problems: asthma
(n = 3), hyperthyroidism (n = 2), partial albinism, carcinoma of
the cervix, seroresistant syphilis, and dermatitis venenata
(n = 1), hypertension (n = 1), alcoholism (n = 1), slight anemia
(n = 1), and multiple sclerosis (n = 1). General medical status
was not reported for 11 patients. Only three cases were reported
to have allergies. Of note, the vast majority of case reports did
not specifically state whether or not the patients had allergies.
Most oral lesions presented as white, homogenous plaques
on the oral mucosa or lip. Occasionally, associated telangiec-
tasias20,22,23 or erosions11 were reported. Labial mucosa, buccal
mucosa, and lip were the most common locations of the OLS
lesions, followed by gingiva and tongue. Notably, floor of the
mouth mucosa was not affected by OLS in any of the patients.
The majority of the patients were asymptomatic; only less than
one-third had symptoms including pain, pruritus, and tightness
when opening the mouth. Gingival involvement by OLS caused
Table 1 Summary of clinical characteristics of OLS patients.
Characteristic
Literature review
(n = 39) + present
cases (n = 2)
Mean age/Median age 34/31 (range 7–70)
Sex F/M (%) 27/14 (66/34%)
Smoker
yes 5 (12%)
no 21 (51%)
not specified 15 (37%)
Lesion site
labial mucosa 20 (49%)
lip 15 (37%)
buccal mucosa 14 (34%)
gingiva 12 (29%)
tongue 12 (29%)
palate 7 (17%)
Symptoms, if reported yes/no (%) 12/26 (32%/68%)
Genital lesions, if reported 7 (18%)
Skin lesions, if reported 12 (31%)
Treatment, if reported yes/no (%) 25/13 (66%/34%)
topical corticosteroids 10 (26%)
intralesional corticosteroid injections 6 (16%)
topical tacrolimus/pimecrolimus 5 (13%)
surgery 5 (13%)
systemic corticosteroids 2 (5%)
other medicationa 10 (26%)
aOther medication included colchicine (n = 2), Solcoseryl, griseoful-
vin, topical testosterone propionate, benzydamine hydrochloride,
topical antibiotics, emollients, methotrexate, pantothenyl alcohol,
topical vitamin A and systemic vitamins A & D.
International Journal of Dermatology 2018, 57, 521–528 ª 2017 The International Society of Dermatology
Review Oral lichen sclerosus Kakko, Salo and Siponen524
soreness associated with tooth brushing in some patients. Gin-
gival recessions, periodontal attachment loss, and tooth mobility
were also reported.12–14,16 In one case, this led to loss of teeth
in the affected area.13 Thirty-one percent of the patients had
skin lesions, and 18% had genital lesions. The oral LS lesions
occurred concurrently with the extraoral lesions in eight cases,
after the onset of extraoral lesions in five cases, and before the
onset of extraoral lesions in two cases.
Two-thirds of the patients received some form of treatment.
The most common medications to manage the OLS symptoms
were topical corticosteroids (n = 10), intralesional corticos-
teroids (n = 6), and topical calcineurin inhibitors tacrolimus
(n = 4) and pimecrolimus (n = 1). Five patients were treated
surgically (Table 1). The other, less commonly used treatments
included systemic corticosteroids (n = 2), systemic colchicine
(n = 2), methotrexate, topical testosterone, systemic vitamin D2
with systemic and topical pantothenyl alcohol, Solcoseryl, and
griseofulvin. Topical corticosteroids resulted in partial response
in 67% (6/9) of the patients, and in no response in 33% (3/9) of
the patients (Table S1). In one patient, the response to topical
corticosteroid was not reported. Intralesional corticosteroids
showed partial response in 67% (4/6) of the patients, and com-
plete response and no response in one patient each. The
patient of Macleod et al.11 was treated with griseofulvin after
topical corticosteroids failed to provide a response, and it
caused some improvement. Systemic corticosteroids used with
intralesional corticosteroids yielded a favorable response in one
report. Tacrolimus ointment resulted in complete resolution of
lesions in one case and partial improvement in one. For two
patients, the response for topical tacrolimus was not reported.
The use of pimecrolimus (after no response to topical corticos-
teroid) showed resolution of lesions with remaining atrophy in
one report. Surgical excision of the lesion resulted in complete
response in 80% (4/5), while in one patient the lesion recurred
after excision. For 71% of the patients, the follow-up duration
was available, and the average time of follow-up reported was
24 months (ranging from 0 to 90 months). None of the OLS
cases were reported to undergo malignant transformation.
Histopathological and immunofluorescence features of OLS
lesions are presented in Table S2. The most consistent
histopathological finding was homogenization/hyalinization of
collagen in the lamina propria, which was found in all the biop-
sies. A band-like, patchy or diffuse chronic inflammatory infil-
trate was present in the connective tissue, often below the
subepithelial hyalinized layer, in all except one case. Epithelial
atrophy and basal hydropic degeneration or vacuolization of
basal cells were found in 63 and 61% of the cases, respec-
tively. Sparseness of elastic fibers was reported in 46% of the
biopsies. Hyperkeratosis was present in 41% of the cases.
Other less common histopathological findings were dilated
blood vessels (27%), subepithelial edema (10%), and subep-
ithelial clefts (10%). Direct IF study was done in four patients
(in 5 biopsies) and was negative except in the first biopsy of the
present case 1, which showed linear IgG and IgM along the
basement membrane.
Discussion
OLS typically presents with whitish, ivory- or porcelain-white
macules or plaques with well-demarcated borders.21,24 These
clinical features may mimic other chronic, white, plaque-type
lesions, such as plaque-like lichen planus, leukoplakia, chronic
hyperplastic candidiasis, oral submucous fibrosis, and localized
scleroderma (morphea).6,12 In addition, some OLS cases may
show characteristics of autoimmune bullous disease.2 Early LS
lesions may histologically have overlapping features with lichen
planus or psoriasis,2 but more mature lesions often show lack
of elastic fibers without band of lymphocytes at epithelium-con-
nective tissue junction, unlike lichen planus.12 For histological
distinction from morphea, Verhoeff’s histochemical staining may
be used to show the loss of elastic fibers in LS biopsies. The
main clinical and histopathological differential diagnoses of OLS
are presented in Table 2.
The age range in OLS is wide, with a mean age of 34.
Hence, OLS patients are typically younger than patients with
lichen planus, leukoplakia, or chronic hyperplastic candidiasis.
OLS patients are often older than oral submucosis fibrosis
Table 2 Main clinical and histopathological differential
diagnoses of OLS.
Differential diagnosis Distinguishing features
Clinical
Chronic hyperplastic
candidiasis
Typically in anterior buccal mucosa
bilaterally, diffuse margins
Frictional keratosis Typically in edentulous alveolar ridge,
diffuse margins
Leukoplakia Wrinkled surface, typically in a middle-
aged or older person, or smoker
Lichen planus (plaque
type)
Symmetrical distribution, includes reticular
areas or white striae, and often
erythematous areas, most are
symptomatic
Morphea Extremely rare. Most cases in the anterior
oral cavity with involvement of the lip,
gingiva and alveolar bone. Often
represents linear morphea.
Oral submucous fibrosis Diffuse lesions, stiffness of the oral
mucosa, stomatopyrosis, trismus
Snuff-dippers pouch Wrinkled or fissured surface in the area
where smokeless tobacco is held
Histopathological
Morphea No focal basal cell degeneration or loss
of elastic fibers in the hyalinized tissue.
Obliteration or narrowing of blood
vessels
Lichenoid lesion/lichen
planus
No subepithelial hyalinization. Band-like
lymphocytic infiltrate immediately
subjacent to the epithelium
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patients, of whom 85% are under 35 years old,25 and child-type
morphea patients, whose mean age is 9.26 Adult-type morphea
patients have, in contrast, a higher mean age (44 years) than
OLS patients.26
Associated autoimmune diseases were found in a few OLS
patients. The present case 1 had MS, which is considered an
immune-mediated, possibly autoimmune disease. Two patients
had hyperthyroidism, which is typically an autoimmune disease.
Of note, many reports did not state whether or not the patients
had any comorbidities. A few papers mentioned that the patients
had no family history of LS. The family history of possible autoim-
mune conditions in the patients of this review was not reported.
Controversy still exists about the possible autoimmune nature
of LS.27 However, female LS patients have an increased preva-
lence of associated autoimmune diseases, whereas in men, this
association is weaker or even nonexistent.28–32 The most com-
mon associated autoimmune pathosis in LS seems to be thyroid
gland disease. Alopecia areata, vitiligo, pernicious anemia,
rheumatoid arthritis, localized scleroderma, ulcerative colitis,
and psoriasis have less often been associated with LS.2,28 Of
note, circulating extracellular matrix protein 1 (ECM1) antibodies
have been observed more often in LS patients compared to
controls.33,34
There is some evidence of genetic background for the devel-
opment of LS. Sherman et al.35 found that 12% of female LS
patients had a positive family history of LS. In addition, several
major histocompatibility complex genes occur more often in LS
patients than in controls.31,32,35–40
IF examination of biopsy was performed in four cases,12,14,41
and only the present case 1 first showed positive findings: linear
IgG, IgM, and fibrin deposits at the basement membrane sug-
gesting pemphigoid. However, the second IF examination
13 months later yielded negative results. The IF findings from
the first biopsy of the present case 1 suggest that autoantibod-
ies against a basement membrane antigen may be present in
LS. In general, direct IF examination in LS is rare. However,
Dickie et al.42 found that a proportion of vulvar LS patients had
positive IgM, C3, and fibrin along the basement membrane in
direct IF. In addition, circulating antibodies against the base-
ment membrane have been observed in vulvar LS.43,44 In this
review, the four cases of OLS analyzed did not show circulating
autoantibodies (Case 1).13,16,45 During follow-up of case 1, no
clinical or histopathological features of pemphigoid have been
observed. Also, the present case 2 was clinically suspected to
have pemphigoid owing to a bullous lesion in the palate. None
of the cases included in the literature review mentioned pem-
phigoid suspicion. However, bullous LS is a known morphologi-
cal variant of LS, with epidermal atrophy and weakening of the
basal cell layer, basement membrane zone, and papillary der-
mis as a possible mechanism behind the bullae formation.46
Also, vacuolar degeneration of the basal cell layer, cleft forma-
tion along the basement membrane, and subepithelial edema
that have been reported in OLS23,47 may cause clinical bullae.
It is therefore possible that the present cases were bullous
forms of LS in their early presentation.
As a result of the small number of patients, randomized con-
trolled trials are difficult to conduct in OLS. Therefore evidence-
based treatment recommendations for OLS are not available.
Topical corticosteroids are considered to be the first-line symp-
tomatic management of LS.2 Recent guidelines on anogenital
LS in women recommend potent to very potent topical steroids
as a treatment of choice.48 In the present review, 16 cases
(42%) were treated with topical or intralesional corticosteroids,
and the results were often favorable. Based on the present
review, intralesional corticosteroid treatment may be more effi-
cient than topical treatment. Although the numbers for treated
patients were small, surgery and topical calcineurin inhibitors
could potentially be of use in the management of OLS. How-
ever, it is recommended that only LS patients with a malignancy
or scarring process should be treated surgically.2 Systemic reti-
noids have been successfully used in the treatment of vulvar
LS.2 The two OLS cases treated with oral vitamin A did not
show any response.18
The risk of genital LS lesions developing malignant change
has been estimated to be 0.3–4.9% for women and 9.3% for
men.2 Questioning the relatively high malignant transformation
rate of LS, a study by van der Nieuwenhof et al.49 shows that a
significant proportion of cases initially diagnosed as vulvar LS,
and that progressed to squamous cell carcinoma, were on revi-
sion in fact diagnosed as vulvar intraepithelial neoplasia. Thus,
LS may not be a precancerous condition as such but a chronic
scarring process in an environment where carcinogenesis could
be enhanced.8 No malignant transformation was reported
amongst the 41 cases of OLS in this review. However, the fol-
low-up of the patients was generally short.
Among the strengths of this study is the systematic search of
three comprehensive databases. There have been other
reviews of OLS,17,21,24,50,51 but these were not systematic
reviews. The weakness of this review is that some relevant arti-
cles may have been excluded owing to limiting the language to
English, and that there might exist articles not included in the
three aforementioned databases. We were able to retrieve infor-
mation from all the case reports and case series that fulfilled
the inclusion criteria; therefore we consider this review to be of
low risk of bias regarding data collection. In addition, all the
data were analyzed by two researchers.
Conclusions
OLS is very rare but should be included in the differential diag-
nosis of white plaque-like lesions of the oral mucosa. In case of
symptomatic lesions, topical or intralesional corticosteroids are
the first-line therapy. Surgical excision, if feasible, may achieve
complete response. Topical calcineurin inhibitors may be used
in cases not responding to topical steroids. Malignant potential
of OLS remains currently unsolved.
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Questions (answers provided following
references)
1. What is the prevalence of oral LS?
a 0.01–0.03%
b 0.1–0.3%
c 0.3–1%
d Unknown
2. The pathogenesis of oral LS is associated with Borrelia
burgdorferi -infections.
a True
b False
3. The majority of patients with oral LS also have skin
lesions.
a True
b False
4. Which of the following statements are correct?
a Most patients with genital LS present symptoms
b Most patients with oral LS are asymptomatic
c Oral LS may cause tooth loss
d Oral LS is a risk factor for oral cancer
5. Clinical differential diagnosis of oral LS includes:
a erythroplakia
b white sponge nevus
c lichen planus
d leukoplakia
6. Biopsy of oral LS is mandatory for diagnosis.
a True
b False
7. Immunofluorescence examination of the biopsy is recom-
mended in oral LS.
a True
b False
8. The most distinctive histopathological feature of LS is
a epidermal atrophy
b lichenoid interface dermatitis
c subepidermal edema
d superficial dermal collagen homogenization
9. Histopathological differential diagnoses of LS includes:
a bullous pemphigoid
b morphea
c lichen planus
d lupus erythematosus
10. In oral LS, topical calcineurin inhibitors are the treatment of
choice.
a True
b False
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Additional Supporting Information may be found in the online
version of this article:
Table S1. Demographic and clinical characteristics of OLS
patients.
Table S2. Histopathological features of OLS lesions.
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